712 related articles for article (PubMed ID: 34691042)
1. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
2. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
3. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
4. Immunization with Epstein-Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge.
Cui X; Cao Z; Ishikawa Y; Cui S; Imadome KI; Snapper CM
Vaccines (Basel); 2021 Mar; 9(3):. PubMed ID: 33808755
[TBL] [Abstract][Full Text] [Related]
5. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
6. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
Front Immunol; 2018; 9():932. PubMed ID: 29765376
[TBL] [Abstract][Full Text] [Related]
7. A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.
Wei CJ; Bu W; Nguyen LA; Batchelor JD; Kim J; Pittaluga S; Fuller JR; Nguyen H; Chou TH; Cohen JI; Nabel GJ
Sci Transl Med; 2022 May; 14(643):eabf3685. PubMed ID: 35507671
[TBL] [Abstract][Full Text] [Related]
8. Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.
Kong XW; Zhang X; Bu GL; Xu HQ; Kang YF; Sun C; Zhu QY; Ma RB; Liu Z; Zeng YX; Zeng MS; Hu ZL
J Virol; 2022 May; 96(9):e0033622. PubMed ID: 35404082
[TBL] [Abstract][Full Text] [Related]
9. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
10. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
11. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
12. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
[TBL] [Abstract][Full Text] [Related]
13. Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule.
Tanner JE; Coinçon M; Leblond V; Hu J; Fang JM; Sygusch J; Alfieri C
J Virol; 2015 May; 89(9):4932-41. PubMed ID: 25694592
[TBL] [Abstract][Full Text] [Related]
14. Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.
Wang M; Jiang S; Han Z; Zhao B; Wang L; Zhou Z; Wang Y
Appl Microbiol Biotechnol; 2016 Feb; 100(3):1221-1230. PubMed ID: 26433969
[TBL] [Abstract][Full Text] [Related]
15. Immunoinformatic and systems biology approaches to predict and validate peptide vaccines against Epstein-Barr virus (EBV).
Ali A; Khan A; Kaushik AC; Wang Y; Ali SS; Junaid M; Saleem S; Cho WCS; Mao X; Wei DQ
Sci Rep; 2019 Jan; 9(1):720. PubMed ID: 30679646
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
17. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
18. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
19. A Neutralizing Antibody Targeting gH Provides Potent Protection against EBV Challenge
Hong J; Zhong L; Zheng Q; Wu Q; Zha Z; Wei D; Chen H; Zhang W; Zhang S; Huang Y; Chen K; Chen J; Li S; Zeng MS; Zeng YX; Xia N; Zhang X; Xu M; Chen Y
J Virol; 2022 Apr; 96(8):e0007522. PubMed ID: 35348362
[TBL] [Abstract][Full Text] [Related]
20. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
